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Abstract
Background: Claudin-6 (CLDN6), a member of claudin transmembrane protein family, has recently been reported
to be undetectable or at low levels in human breast cancer cell lines and tissues and plays a role in suppression of
migration and invasion in breast cancer cells. In addition, it is reported that CLDN6 expression is regulated by DNA
methylation in various human cancers and cell lines. However, it is unclear how DNA methylation regulates CLDN6
expression. Here we show the mechanism by which DNA methylation regulates CLDN6 expression in human breast
cancer cell line MCF-7.
Methods: RT-PCR, Western blot and immunofluorescent staining were utilized to investigate CLDN6 expression in breast
cancer tissues and MCF-7 cells. Methylation-Specific PCR (MSP) was applied to determine DNA methylation status in
CLDN6 gene promoter region. Wound-healing assay and invasion assay were utilized to test mobility of MCF-7 cells
treated with 5-aza-dC (DNA methyltransferase inhibitor). MeCP2 binding, H3Ac and H4Ac in CLDN6 promoter region
were analyzed by ChIP assay. Nuclease accessibility assay was performed for analysis of the chromatin conformation of
CLDN6 gene. To study the role of CLDN6 in malignant progression, we used RNAi to knockdown CLDN6 expression in
MCF-7 cells treated with 5-aza-dC, and examined the mobility of MCF-7 cells by wound-healing assay and invasion
assay.
Results: 5-aza-dC and TSA (histone deacetylase inhibitor) application induced CLDN6 expression in MCF-7 cells
respectively and synergistically. 5-aza-dC treatment induced CLDN6 demethylation, inhibited MeCP2 binding to
CLDN6 promoter and increased H3Ac and H4Ac in the promoter. In addition, TSA increased H4Ac, not H3Ac in the
promoter. The chromatin structure of CLDN6 gene became looser than the control group after treating with 5-aza-dC
in MCF-7 cells. 5-aza-dC
up-regulated CLDN6 expression and suppressed migration and invasion in MCF-7 cells, whereas CLDN6 silence restored
tumor malignance in MCF-7 cells.
Conclusions: DNA methylation down-regulates CLDN6 expression through MeCP2 binding to the CLDN6 promoter,
deacetylating H3 and H4, and altering chromatin structure, consequently promoting migratory and invasive phenotype
in MCF-7 cells.
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Background
Claudins are structurally and functionally crucial compo-
nents of tight junctions, which play important roles in regu-
lating paracellular permeability and maintaining cell
polarity in epithelial and endothelial cell sheets. Abnormal
breast epithelial cell polarity causes epithelial-mesenchymal
transition (EMT), and promotes tumor metastasis and
invasion [1, 2]. The CLDNs family consists of 27 members,
which are expressed in a tissue- and cell-specific manner
[3, 4]. Loss of CLDNs expression has also been reported in
several malignancies, e.g. loss of claudin 1 expression in
breast cancer and in head and neck cancer.
In the present study, the expression of CLDN6 was un-
detectable or at low levels in human and rat mammary
cancer cell lines and tissues [5]. Besides, tissues derived
from breast carcinoma with lymph node metastasis were
also accompanied with decreasing expression of CLDN6.
It is reported that the CLDN6 over-expression could
inhibit migratory and invasive abilities in MCF-7 cells
with stable CLDN6 expression [6]. Similarly, CLDN6 ex-
pression may suppress breast tumorigenesis [7]. These
results revealed that CLDN6 over-expression might con-
tribute to suppression of breast cancer progression. Never-
theless, the mechanism for aberrant CLDNs expression has
not been explored yet. Silence of tumor suppressor gene
may relate to the epigenetic events. Cancer epigenetic
events such as aberrant DNA methylation and histone
modification lead to inactivation of specific tumor-
suppressor genes [8, 9]. DNA methylation is an important
epigenetic modification that affects chromatin structure
and gene expression [10]. Tumor suppressor gene silence
is involved in carcinogenesis, drug resistance and recur-
rence [11–13]. High levels of methylation were associated
with disease recurrence. Particularly, MLH1, ATM and
FHIT gene promoters are found to be significantly hyper-
methylated in recurring adenomas [14]. DNA methylation
leads to transcriptional repression either by methyl groups
which interfere with protein binding to its cognate DNA
sequence or by recruiting proteins that specifically
recognize methylated CpGs (mCpGs) [15], the proto-
type of which is methyl-CpG-binding protein 2
(MeCP2). In the enzymatic mode, MeCP2 specifically
targets mCpGs and determines repressive heterochro-
matin by interacting with co-repressor mSin3A, which is
a part of a large complex containing histone deacetylases
(HDACs) [16, 17]. MeCP2 can also recruit histone meth-
yltransferase that methylates local H3 lysine9 for strength-
ening the repressive state [17].
In our study we firstly examined CLDN6 expression and
methylation status at CLDN6 gene CpG sites in breast
cancer tissues and MCF-7 cells to study relationship be-
tween CLDN6 expression and DNA methylation. To ex-
plore the molecular mechanism of DNA methylation of
CLDN6, we investigated the relevance among CLDN6,
MeCP2, H3Ac and H4Ac in MCF-7 cells. Our investiga-
tion showed that CLDN6 expression was associated with
DNA methylation in breast cancer tissues and cells. More-
over, DNA methylation of CLDN6 promoter down-
regulated its expression through binding with MeCP2,
deacetylating H3 and H4, and altering chromatin struc-
ture, ultimately resulted in malignant phenotype in MCF-
7 cells. In addition, we demonstrated that DNA methyl-
transferase inhibitor 5-aza-dC and histone deacetylase in-
hibitor TSA treatment induced CLDN6 expression
respectively and synergistically, and suppressed migration
and invasion in MCF-7 cells. However, knockdown
CLDN6 expression with 5-aza-dC treatment would en-
hance the invasive and migratory abilities.
Methods
Patients’ samples and cell culture
Paraffin-embedded tissues from 30 specimens of breast
cancer including 19 specimens with lymph node metasta-
sis, 11 specimens without lymph node metastasis and 10
specimens of breast pericarcinomatous tissues were col-
lected from patients at the Third Hospital of Jilin Univer-
sity with approval by the institutional review board (IRB).
None of the patients received neo-adjuvant therapy. The
patients’ medical records were reviewed to obtain their
age, tumor status and clinical stage. All the cancer cases
were classified and graded according to the International
Union Against Cancer (UICC) staging system for breast
cancer.
Human breast epithelial cell line HBL-100, human
breast adenocarcinoma cell line MCF-7 and ovarian can-
cer cell line COC1 were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (GIBCO, USA) supplemented
with 10 % fetal bovine serum (FBS) (BD, Tokyo, Japan)
at 37 °C in a humidified 5 % CO2 atmosphere.
Reverse transcription—PCR (RT- PCR)
Total RNA was isolated using TRIzol reagent (Invitrogen,
USA). The concentration of RNA was measured by the
absorbance at 260 nm. 0.5 μg total RNA was reverse
transcribed using M-MLV reverse transcriptase (TaKaRa,
Japan) and random primer (TaKaRa, Japan) at 42 °C for
60 min and 1 μl of the final cDNA reaction was used for
subsequent PCR reaction using Taq DNA polymerase
(TaKaRa, Japan). Amplification conditions were as follows:
PCR reactions were denatured at 94 °C for 2 min, followed
by 28 cycles of 94 °C for 30s, 50–60 °C for 30s, and 72 °C
for 1 min. This was followed by a final extension of 10 min
at 72 °C. β-actin and GAPDH were used as endogenous
control.
The PCR primers were summarized in Table 1. The reac-
tion products were resolved on 1.5 % agarose gels and visu-
alized by staining with ethidium bromide, the image was
observed and photographed under viltalight lamp using
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Gel Imaging System (Bio-Rad Laboratories Inc, Hercules,
CA, USA). The results were analyzed by Quantity One
4.4.1 software (Bio-Rad Laboratories Inc, Hercules, CA,
USA).
Western blot
Total protein was extracted using 400 μl protein extrac-
tion fluid (HuaTe Sheng, China) with 40 μl (10 mM) phe-
nylmethanesulfonyl fluoride (PMSF) according to the
supplier’s instructions. The concentration of the total pro-
tein was determined using BCA Protein Assay Kit (Pierce
Chemical Co, USA). 60 μg of denatured total protein of
each sample per lane were resolved by SDS-PAGE (15 %
acrylamide), and transferred to a nitrocellulose membrane
(Millipore, USA) using a Semi-DRY Transfer cell (Bio-Rad
Laboratories Inc, Hercules, CA, USA). The membrane
was blocked with 5 % defatted milk (in 25 mM Tris,
pH 8.0, 125 mM NaCl, 0.1 % Tween 20) for 1 h at room
temperature then incubated with 1:1000 diluted anti-
CLDN6 (Santa Cruz Biotechnologies) antibody at 4 °C
overnight. After washing three times with PBS, the mem-
brane was incubated with a horseradish peroxidase
conjugated anti-goat IgG (1:1000, Santa Cruz Biotech-
nologies) secondary antibody at room temperature for
1 h. After washing, the immunoreactive bands were vi-
sualized using an ECL western blot system (GE, USA)
and exposed to X-ray film (Estman Kodak). Anti-β-
actin (Santa Cruz Biotechnologies) antibody was used
as the endogenous control.
Methylation-specific PCR analysis
Genomic DNA was extracted from MCF-7 cells using
Wizard Genomic DNA Purification Kit (Promega), and
1 μg DNA was denatured by 0.3 M NaOH for 10 min at
37 °C. All samples were incubated at 50 °C for 16 h after
adding hydroquinone (Sigma, USA) and sodium bisulfate
(Sigma, USA). Methylation-specific PCR (MSP) was per-
formed to analyze the methylation status at CpG-rich
area of CLDN6 promoter. Primers specific for unmethy-
lated DNA and methylated DNA were summarized in
Table 1. PCR was carried out for 30 cycles at 95 °C for
30s, 58 °C for 30s, followed by a final extension at 72 °C
for 10 min. PCR products were electrophoresed on
1.5 % agarose gel stained with ethidium bromide.
5-Aza-2’-deoxycytidine (5-aza-dC) and Trichostatin A (TSA)
Treatment
MCF-7 cells were treated with various concentrations (0,
2.5, 5, 10, 15, and 20 μM) of DNA methyltransferase in-
hibitor, 5-aza-dC (Sigma, USA) for 24 h or 48 h, and vari-
ous concentrations (0, 0.075, 0.125, 0.25, 0.5, and 1 μM) of
histone deacetylase inhibitor, TSA (Sigma, USA) for 48 h
respectively, and treated with 20 μM of 5-aza-dC with
0.125 μM TSA for 48 h.
Table 1 Primers for PCR assay
Gene name Sequence (5’→ 3’)
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Immunofluorescent staining
MCF-7 cells were seeded onto small coverslips and
treated with 17-β-estradiol at 0.005 μM for 24 h. After
washing three times with PBS, the cells were fixed with
4 % paraformaldehyde for 30 min at room temperature.
The cells were incubated with 0.3 % H2O2 and 30 μl
goat serum 30 min respectively. The cells were incu-
bated with 1:500 diluted anti-CLDN6 antibodies (Santa
Cruz Biotechnologies) at 4 °C overnight and 1:50 diluted
Rhodamine (red) -conjugated anti-goat IgG was used as
a secondary antibody. The cells were photographed by
confocal microscope (OLYMPUS, Japan).
Wound-healing assay
Cancer cells were cultured in monolayer at 90 % conflu-
ence on gridded plastic dishes, and then wounded by
scratching them with a 200 μl pipette tip, and then washed
3 times. The cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (GIBCO, USA) supplemented
with fetal bovine serum free (BD, Tokyo, Japan) at 37 °C
in a humidified 5 % CO2 atmosphere. The wounds were
photographed at 0 and 24 h.
Invasion assay
The invasive potential of cancer cells was determined
using Boyden chamber. MCF-7 cells were first cultured in
DMEM with 10 % fetal bovine serum to 90 % confluence,
and then washed 2 times with PBS. Then the cells were
cultured in FBS free medium for 24 h at 37 °C in a hu-
midified 5 % CO2 atmosphere. The medium containing
chemotactic factors from the cell culture was collected.
Matrigel was added to the upper boyden chamber of 24-
well and incubated at 37 °C for 30 min. Then it was
followed by adding medium with chemotactic factor to
24-well, putting MCF-7 cells suspension onto the matrigel
and incubating at 37 °C in a humidified 5 % CO2 atmos-
phere 24 h. In the end, the invasive cells were counted.
ChIP Assay
The chromatin immunoprecipitation was performed using
the EZ Magna ChIP G chromatin immunoprecipitation kit
(Millipore). Briefly, MCF-7 cells were treated with 20 μM
5-aza-dC. The protein-DNA complexes of cells were
cross-linked using formaldehyde at room temperature
for 10 min. The genomic DNA of lysed cells was sheared
to 200–1000 bp by sonication. The final lysate was incu-
bated with MeCP2-, and MBD2-specific antibodies and
precipitated with protein G magnetic beads. After washing
three times, DNA-protein complexes were reversely cross-
linked, and genomic DNA was extracted with Wizard Gen-
omic DNA Purification Kit (Promega, USA), and eluted in
50 μl of TE buffer. 0.5 μg DNA was used for PCR as de-
scribed above. The PCR primers were summarized in
Table 1. The products of PCR amplification were separated
on 2.0 % agarose gel and visualized using ethidium
bromide and UV light. The results were analyzed as
described above.
Quantitative RT-PCR
To quantify amplified signals from the CLDN6 5’ flanking
region and promoter in MCF-7 cells, quantitative PCR
was undertaken by using the iCycleriQ real-time PCR de-
tection system (Bio-Rad, Hercules, CA, USA) and an iQ
SYBR green master mix (Bio-Rad, Hercules, CA, USA).
The PCR cycles were 95 °C for 2 min and then 40 cycles
of 95 °C for 15 s, 60 °C for 30s. The primers were designed
to amplify 100 bp per primer pair and summarized in
Table 1. The specificity of amplification for each pair was
confirmed by separation of amplified fragments by agarose
electrophoresis and by performing melting curve analysis.
PCR assays were run in triplicate.
Nuclease accessibility assay
The nuclei of MCF-7 cells were prepared as described [18].
Nuclei (100 μg DNA) were treated with 500 units of nucle-
ase S7 (TaKaRa, Japan) for 10 min at 37 °C to produce
mononucleosomal fragments. The mixture was treated with
proteinase K, and DNA was purified using phenolchloro-
form. The digested product was electrophoresed on 1.2 %
agarose gel stained with ethidium bromide. To analyze the
extent to which different parts of the CLDN6 promoter re-
gion were digested by S7 nuclease, we used real-time PCR
as described above. PCR assays were run in triplicate and
the relative abundance of CLDN6 promoter regions was es-
timated from the threshold amplification cycle number, Ct,
using software supplied with iCycler IQ. The differences
between Ct values obtained from MCF-7 cells treated with
20 μM 5-aza-dC and control cells were plotted against cor-
responding primer pairs that amplified small, overlapping
sequences within the 5’flanking region of the CLDN6 gene
(primer sequences used in this assay are available upon
request). The primers were summarized in Table 1.
Short hairpin RNA (shRNA) transfection
Four shRNAs were designed, based on the claudin-6
mRNA sequence NM_021195 and were constructed
into the vector pGCsilencer™U6/Neo/GFP (GeneChem,
Shanghai, China). MCF-7 cells were transfected with
shRNA-CLDN6 using SuperFect Transfection Reagent
(QIAGEN, USA). A negative control cell line was gen-
erated by transfecting cells with the vector constructed
by targeting a sequence that did not yield any appre-
ciable knockdown of the protein production. shRNA
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CTGCATCTGgc and iv) caGTGCAAGGTGTACGA
CTCATTCAAGAGATGAGTCGTACACCTTGCACtg.
shRNA-mediated suppression of CLDN6 expression
was confirmed using RT-PCR and Western blot as de-
scribed above.
Statistical analysis
Counts and rates were calculated for categorical variables.
The Chi-square test was used to compare categorical vari-
ables among different groups. All statistical analyses were
performed using the SPSS software package (version
13.0.0). P values less than 0.05 were considered statistically
significant.
Results
CLDN6 expression is down-regulated in breast cancer
tissues and MCF-7 cells, correlating with DNA methylation
The CLDN6 protein level was higher in breast pericarci-
nomatous tissues compared to breast cancer tissues
(Fig. 1a). CLDN6 expression level is lower in the cancer
samples with lymph node metastasis than in those without
lymph node metastasis (Table 2). In addition, CLDN6 ex-
pression was inversely correlated with breast cancer cell
metastasis, indicating that CLDN6 might play an important
role in suppressing breast cancer progression.
The comparison of mRNA and protein level of
CLDN6 expression among breast cancer MCF-7 cells,
HBL-100 cells (human normal breast cells) and COC1-
cells (human cervical cancer cells as tissue-specific con-
trol) showed that CLDN6 expression was decreased in
MCF-7 as compared with HBL-100 and COC1, indicat-
ing that reduction of CLDN6 expression had tissue- and
cell-specificity, which was consistent with clinical assays
(Fig. 1b).
Aberrant DNA methylation such as localized CpG is-
land hypermethylation leads to inactivation of specific
tumor-suppressor genes [19–21]. To investigate CpG is-
land distribution, we used Methyl Primer Express soft-
ware to search CpG islands in CLDN6 promoter region
and found CpG islands were enriched in the region.
Then we hypothesized that the low expression of
CLDN6 might be correlated with DNA methylation in
breast cancer. Figure 1c showed DNA methylation of
CLDN6 in breast pericarcinomatous tissues and cancer
tissues by MSP assay respectively. 20 % of 10 breast peri-
carcinomatous tissues showed CLDN6 methylation,
Fig. 1 CLDN6 expression is down-regulated drastically by DNA hypermethylation in breast cancer tissues and MCF-7 cells. a CLDN6 expression
was significantly higher in breast pericarcinomatous tissues than that in breast cancer tissues by western blot. From lane 1 to lane 7 were represented
of different tissue samples. P = 0.021 < 0.05. b The expression of CLDN6 in HBL-100、MCF-7 and COC1 cells (as tissue-specific control), determined by
RT-PCR and Western blot assay. Differently with HBL-100 cells, CLDN6 expression was undetectable or low levels in MCF-7 cells. c CLDN6 DNA
methylation status was determined in breast pericarcinomatous tissues and breast cancer tissues by MSP. (D) CLDN6 DNA methylation status
was determined by MSP analysis in HBL-100, MCF-7 and COC1 cells. CLDN6, claudin-6; MSP, Methylation-Specific PCR
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while 60 % of 30 breast cancer tissues showed CLDN6
methylation (Table 3). In addition, 69.9 % of 23 breast can-
cer tissues showed DNA methylation with low expression
of CLDN6, indicating that CLDN6 expression was
negatively associated with DNA methylation (Table 4).
Figure 1d showed that CLDN6 CpG sites were hyper-
methylated in MCF-7 cells. The results suggested that
dramatically down-regulated CLDN6 expression may
be correlated with DNA methylation of CLDN6.
5-aza-dC application induces CLDN6 expression and
inhibits migratory and invasive abilities in MCF-7 cells
To investigate whether DNA hypermethylation could lead
to reducing CLDN6 expression, we treated MCF-7 cells
with DNA methyltransferase inhibitor 5-aza-dC [22]. Our
results showed that treatment with 5-aza-dC increased
CLDN6 mRNA expression in a dose- and time-dependent
manner by promoting demethylation of the CLDN6 CpG
sites. Treatment with 20 μM 5-aza-dC for 48 h
increased CLDN6 mRNA and protein expression dra-
matically (Fig. 2a, b and c), and membranous expres-
sion of CLDN6 was detected by immunofluorescence
(Fig. 2d). In addition, treatment with 20 μM 5-aza-dC
for 48 h promoted demethylation of CLDN6 CpG sites
(Fig. 2e). To evaluate whether demethylation of CLDN6
plays a role in breast cancer progression, we analyzed in-
vasive and migratory abilities in MCF-7 cells treated with
5-aza-dC. Consistently with our hypothesis, DNA demeth-
ylation of CLDN6 indeed inhibited migration and invasion
in MCF-7 cells (Fig. 2f and g).
TSA application induces CLDN6 expression in MCF-7 cells
To investigate whether TSA plays a role in up-regulation
of suppressor gene, we treated MCF-7 cells with TSA to
investigate the involvement of histone deacetylation in
CLDN6 gene silencing. After the treatment of MCF-7 cells
with 125nM TSA for 48 h, mRNA and protein expression
of CLDN6 were both increased (Fig. 3a, b and c), and
Table 3 DNA methylation of CLDN6 in breast pericarcinomatous
tissues and cancer tissues
Type of tissues Methylation Positive rate
– +
Breast cancer 12/30 18/30 60 %
Pericarcinomatous tissues 8/10 2/10 20 %
χ2 = 8.27,P = 0.0268 < 0.05
Table 4 DNA methylation associating with CLDN6 expression in
breast pericarcinomatous tissues and cancer tissues
CLDN6 expression DNA Methylation P value
- +
Low 7/23 16/23 P < 0.05
High 13/17 4/17
Pearson’s chi-square (χ2) test,P = 0.033 < 0.05
Table 2 Clinical pathological characteristic of breast cancer patients associating with CLDN6 expression
Characteristic N CLDN6 Expression P value
High Low
Breast cancer tissues 30 7 (23.33 %) 23 (76.67 %)
Pericarcinomatous tissues 10 10 (100 %) 0 (0 %) P < 0.05
Age (years)
20–40 9 2 (22.22 %) 7 (77.78 %)
40–60 14 3 (21.43 %) 11 (78.57 %)
60–80 7 2 (28.57 %) 5 (71.43 %) P > 0.05
Tumor status
T1 13 2 (15.38 %) 11 (84.62 %)
T2 12 4 (33.33 %) 8 (66.67 %)
T3 5 1 (20 %) 4 (80 %) P > 0.05
Clinical stage
Is-I 14 4 (28.57 %) 10 (71.43 %)
II-IV 16 3 (18.75 %) 13 (81.25 %) P > 0.05
Node status
+ 19 2 (10.53 %) 17 (89.47 %)
– 11 5 (45.45 %) 6 (54.55 %) P < 0.05
P value was measured with student’s t test. Significance of association was determined using a χ2 test
Liu et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:120 Page 6 of 13
membranous expression of CLDN6 was detected by im-
munofluorescence (Fig. 3d). Moreover, we found that sim-
ultaneous treatment of both 5-aza-dC and TSA enhanced
CLDN6 expression synergistically (Fig. 3e, f and g). In
summary, these results indicated that down-regulation of
CLDN6 expression might be partially correlated with his-
tone deacetylation in MCF-7 cells.
Methylated DNA recruits MeCP2, and deacetylates H3Ac
and H4Ac at CLDN6 promoter
To further elucidate the mechanism of regulating CLDN6
methylation in breast cancer cells, we performed ChIP
assay in MCF-7 cells treated with 5-aza-dC. MeCP2 bind-
ing to CLDN6 promoter was dramatically reduced in
MCF-7 cells with 5-aza-dC treatment compared with
Fig. 2 5-aza-dC application induces CLDN6 expression and inhibits migration and invasion abilities in MCF-7 cells. a RT-PCR was used to display
the effect of 5-aza-dC on CLDN6 expression. 5-aza-dC application induced CLDN6 expression in a concentration- and time-dependent manner.
Lane 1 was control group; lanes 2 to 6 were treated with 5-aza-dC group (2: 2.5 μM; 3: 5 μM; 4: 10 μM; 5: 15 μM; 6: 20 μM). Data in lane 6 showed
that 20 μM 5-aza-dC treatment had the greatest effect on inducing CLDN6 expression. b CLDN6 expression was determined in MCF-7 cells treated
with 20 μM 5-aza-dC for 1 to 72 h. Lane 1 was control group, lane 2 to 5 were 20 μM 5-aza-dC treated group (2: 12 h; 3: 24 h; 4: 48 h; 5: 72 h). Data in
lane 5 showed that 20 μM 5-aza-dC for 48 h had the greatest effect on inducing CLDN6 expression. c CLDN6 protein expression was significantly
up-regulated in MCF-7 cells treated with 5-aza-dC at 20 μM for 48 h by western blot. d Immunofluorescent staining showed CLDN6 expression
at the membranes of MCF-7 cells after treated with 20 μM 5-aza-dC for 48 h using × 100 magnification. e CLDN6 DNA methylation status was
determined by MSP analysis between control group and treatment with 5-aza-dC 20 μM for 48 h group. 5-aza-dC treating group increased
demethylation of CLDN6 CpG sites. f MCF-7 cells treated with 5-aza-dC were examined the ability of cell migration compared with control by
wound-healing assay. g The invasive cells treated with 5-aza-dC were remarkably lower invasive ability than control group by invasion assay.
*P < 0.05. CLDN6, claudin-6; 5-aza-dC, 5-Aza-2’-deoxycytidine; MSP, Methylation-Specific PCR
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those without the treatment (Fig. 4a, b and c). Moreover,
5-aza-dC application increased H4Ac and H3Ac in
CLDN6 promoter region, but TSA application increased
only H4Ac in the region. Besides, the combination treat-
ment with 5-aza-dC and TSA increased H3Ac and H4Ac
in CLDN6 promoter synergistically (Fig. 4d and e). To-
gether, these results demonstrated that CLDN6 expression
was down-regulated via recruiting MeCP2 and deacetylat-
ing H3Ac and H4Ac for stability of methylation.
CLDN6 promoter is more accessible after micrococcal
nuclease digestion in MCF-7 cells with 5-aza-dC treatment
To obtain information about nucleosomal organization
of CLDN6 promoter, MCF-7 cells were treated with
micrococcal S7 nuclease to digest internucleosomal DNA
(Fig. 5a). Mononucleosomal DNA was isolated and ampli-
fied by utilizing overlapping and closely spaced (~100 bp)
primer pairs. If the region to be amplified were more
accessible by the nuclease in one cell type and less access-
ible in other cell types, we would detect their difference in
the number of cycles required to reach the threshold level
(Ct) in a quantitative PCR. Therefore, positive numbers
obtained after subtraction of the control group Ct value
from the Ct value from MCF-7 cells with 5-aza-dC treat-
ment, indicate that this DNA region was more accessible,
whereas negative values indicate the opposite. We found
that the region from +1 to +400 bp was more open to nu-
clease digestion in MCF-7 cells with 5-aza-dC treatment
compared to control group (Fig. 5b). This result suggests
that 5-aza-dC might alter CLDN6 chromatin structure for
its transcription in breast cancer cells.
DNA demethylation restores CLDN6 expression, inhibiting
invasion and migration in MCF-7 cells
We knockdowned CLDN6 and confirmed its efficiency at
mRNA and protein levels in MCF-7 cells treated with 5-
Fig. 3 CLDN6 expression is down-regulated drastically correlating with histone deacetylization in breast cancer cells. a RT-PCR was determined
effects of TSA treatment on CLDN6 expression in MCF-7 cells. TSA application induced CLDN6 expression in a concentration- and time-dependent
manner. Lane 1 was control group, lanes 2 to 6 were TSA treated group (2: 75 nM; 3: 125 nM; 4: 250 nM; 5: 500 nM; 6: 1000 nM). Data in lane 3 showed
that 125 nM TSA had the greatest effect on inducing expression of CLDN6. b CLDN6 expression in MCF-7 cells treated with 125 nM TSA for 1 to 72 h.
Lane 1 was control group, lane 2 to 6 were 125 nM TSA treated group (2: 12 h; 3: 24 h; 4: 48 h; 5: 72 h). Data in lane 5 showed that 125 nM TSA for
48 h had the greatest effect on inducing expression of CLDN6. c Western blot assay examined CLDN6 protein expression was significantly
up-regulated in MCF-7 cells treated with TSA at 125 nM for 48 h. d Immunofluorescent staining showed expression of CLDN6 at the membranes of
MCF-7 cells treated with 125 nM TSA for 48 h using × 100 magnification. e RT-PCR was used to determine the expression of CLDN6 in MCF-7cells
treated with 5-aza-dC and TSA respectively or synergistically. f Western blot assay examined CLDN6 protein expression in MCF-7cells treated
with 5-aza-dC and TSA respectively or synergistically. g Immunofluorescent staining showed expression of CLDN6 at the membranes in
MCF-7 cells treated with 5-aza-dC and TSA respectively or synergistically using × 400 magnification. CLDN6, claudin-6; TSA, Trichostatin A;
5-aza-dC, 5-Aza-2’-deoxycytidine
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aza-dC, (Fig. 6a and b) and found knockdown of CLDN6
restored migratory and invasive abilities (Fig. 6c and d).
All together, we demonstrated that DNA methylation
down-regulated CLDN6 expression via recruiting MeCP2
and deacetylating H3Ac and H4Ac, indicating loss of
CLDN6 expression could further destroy integrity of cells
by losing cell polarity and cell adhesion, and promote ma-
lignant progression. It is interesting that DNA methyltrans-
ferase inhibitor 5-aza-dC and histone deacetylase inhibitor
TSA could induce CLDN6 re-expression partially and 5-
aza-dC could inhibit invasion and migration of MCF-7
cells. Overall, these data suggest that CLDN6 plays a critical
role in suppressing malignant progression in MCF-7 cells.
Discussion
In our previous work, we have identified CLDN6 as a po-
tential mammary cancer suppressor gene, which may con-
tribute to mammary cancer resistant phenotype observed
in human and rat mammary cancer cell lines [5, 6]. How-
ever, its regulation mechanisms are elusive. Therefore, in-
vestigation of the mechanism of regulating CLDN6
expression may help in understanding of breast tumori-
genesis and provide new opportunities for detection and
therapy of this disease. Promoter hypermethylation, with
MeCPs binding and histone deacetylation, has been iden-
tified as a major epigenetic event associated with the loss
of tumor suppressor gene expression during cancer pro-
gression [23–25]. DNA methylation-dependent repression
of transcription can be mediated by several mechanisms.
At first, DNA methylation at binding sites of transcription
factors can repress the transcription factor. A methylated
target sequence can interfere transcription factors such
as Sp1/Sp3, E2F and CREB to bind to their binding sites
and to prevent transcriptional activation [17, 26]. A more
elaborate mechanism is that methyl-CpG binding pro-
teins such as MeCP2 and MBD2, a member of the MeCP1
complex [27], are recruited to the methyl-CpG
sequence and then these methyl-CpG binding proteins are
associated with various chromatin modifiers to establish a
repressive chromatin environment [18, 27–29].
In this report, we examined CLDN6 expression in HBL-
100, MCF-7 and COC1 cells by RT-PCR and western blot
Fig. 4 CLDN6 was down-regulated via recruiting MeCP2 and deacetylating H3Ac and H4Ac for DNA methylation stability. a The molecular size of
shared genomic DNA of MCF-7 cells treated with DMSO (as control) and 5-aza-dC. b Effect of 5-aza-dC on binding of MeCP2 to CLDN6 was
analyzed using ChIP assay. The binding of RNA polymerase II and IgG to the GAPDH promoter was used as a positive or a negative control.
c Quantitative analysis of images presented in (b). d Analysis of CLDN6 promoter occupancy by H3Ac and H4Ac. ChIP was used to analyze the
interactions of H3Ac and H4Ac with the CLDN6 proximal promoter in MCF-7 cells treated with 20 μM 5-aza-dC and 125nM TSA for 48 h respectively or
synergistically. Effect of 5-aza-dC and TSA on binding of H3Ac and H4Ac to CLDN6 was analyzed using ChIP assay. The binding of RNA polymerase II
and IgG to the GAPDH promoter was used as a positive and a negative control. e Quantitative analysis of images presented in (d). *P < 0.05. CLDN6,
claudin-6; 5-aza-dC, 5-Aza-2’-deoxycytidine; TSA, Trichostatin A; MeCP2, methyl-CpG-binding protein 2; H3Ac, Histone 3 acetylation; H4Ac, Histone
4 acetylation
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assay (Fig. 1b) and the methylation status at the CLDN6
gene CpG sites and found that MCF-7 cells did not express
CLDN6 with methylation at the CLDN6 CpG sites. HBL-
100 and COC1 cells with CLDN6 expression exhibited
unmethylation at CLDN6 CpG sites. To determine the con-
tribution of DNA methylation and histone modification in
CLDN6 expression, we treated MCF-7 cells with 5-aza-dC
and TSA. The CLDN6 expression was up-regulated by
treating with 5-aza-dC and TSA respectively and synergis-
tically, indicating that DNA methylation and histone deace-
tylation play an essential role in CLDN6 silence.
Our data indicate that the methylation of CpG dinu-
cleotides in the CLDN6 promoter may not directly
interfere with the binding ability of transcription fac-
tor, but methyl-CpG binding protein may interfere with
it. However, the role of methyl-CpG-binding proteins in
the decrease of transcription factor binding in the meth-
ylated CLDN6 promoter is not clear. Nevertheless, our
ChIP assay suggested that MeCP2 did interact with
CLDN6 proximal promoter in MCF-7 cells in vitro, but
not in 5-aza-dC treatment group. These results demon-
strated that methylated CLDN6 promoter interfered
transcription of CLDN6, which was likely intermediated
by MeCP2 protein.
Methyl-CpG binding proteins (MBPs) bind to regions of
methylated DNA and form complexes with HDACs, then
a
b
Fig. 5 5-aza-dC may alter the chromatin structure of CLDN6 for transcription in MCF-7 cells. a MCF-7 cells were treated with micrococcal S7 nuclease
to produce mononucleosomal genomic DNA fragments (100 ∼ 200 bp). b Primer pairs were designed between -400- + 400 bp of CLDN6 proximal
promoter. Micrococcal S7 nuclease preferentially digested DNA that was not organized in nucleosomes. Hence, DNA organized in nucleosomes would
be less prone to nuclease digestion and amplified to the qPCR threshold at a lower Ct compared to the less organized DNA. c Purified mononucleosomal
DNA was amplified using primer pairs (depicted in (b)) and the resulting product was quantified using SYBR green dye in a quantitative PCR. The difference
in Ct between 5-aza-dC treating MCF-7 and DMSO treating MCF-7 cells (as control) for each primer pair was plotted. The positive numbers suggested that
in 5-aza-dC treating MCF-7 cells this part of the DNA was less organized into nucleosomes and more prone to nuclease digestion compared to control
cells. CLDN6, Claudin-6; 5-aza-dC, 5-Aza-2’-deoxycytidine
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resulting in histone deacetylation downstream of the
methylated CpG sequence and transcriptional silencing of
that region of the genome [30]. Similarly, proteins that
either bind modified histones such as heterochromatin
protein 1 (HP1) or directly modify histones such as ly-
sine specific demethylase 1 (LSD1) and protein arginine
methyltransferase 5 (PRMT5), can recruit DNA methyl-
transferases to induce DNA methylation in the silenced
Fig. 6 CLDN6 acts as a critical role in suppressing tumorigenesis in breast cancer cells. a MCF-7 cells were mock transfected or transfected with
siRNA for CLDN6. Nontargeting siRNA was used as negative control. Total RNA was extracted 48 h after transfection, and CLDN6 mRNA levels
were determined using quantitative RT-PCR. b Total protein was extracted 48 h after transfection, and CLDN6 expression at protein levels was
determined using western blot assay. c Knockdown of CLDN6 in MCF-7 cells, the migratory abilities of treating with 5-aza-dC group and 5-aza-dC
with vector group were significantly reduced than control and 5-aza-dC with CLDN6 RNAi group. d Knockdown of CLDN6 in MCF-7 cells, the invasive
abilities of treating with 5-aza-dC group and 5-aza-dC with vector group were significantly reduced than control and 5-aza-dC with CLDN6 RNAi group.
*P < 0.05. CLDN6, Claudin-6; 5-aza-dC, 5-Aza-2’-deoxycytidine
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gene [31–33]. Furthermore, our data showed TSA
could up-regulate CLDN6 expression, indicating that
not only DNA methylation, but also histone deacetyla-
tion play an essential role in CLDN6 silencing in MCF-
7 cells. We determined H3Ac and H4Ac in CLDN6 pro-
moter in MCF-7 cells with 20 μM 5-aza-dC and 125nM
TSA treatment for 48 h respectively and simultaneously.
H4Ac in CLDN6 promoter was induced by using 5-aza-
dC and TSA respectively and simultaneously, but H3Ac in
CLDN6 was induced only with 5-aza-dC treatment, sug-
gesting that deacetylation of H3Ac might depend on DNA
methylation to repress CLDN6 expression, but H4Ac
might not rely on DNA methylation, and might inde-
pendently regulate CLDN6 expression. Histone modifica-
tion may repress transcriptional complexes to combine
with gene promoter by changing the chromatin structure
in nucleosomes and in turn making the complexes in-
accessible to the transcriptional machinery. Our nucleo-
somal mapping experiment indicated that indeed the DNA
methylation of CLDN6 promoter in MCF-7 cells existed in
a more organized nucleosomal form that is more resistant
to endonuclease digestion. Collectively, our results indi-
cated that 5-aza-dC and TSA treatment in MCF-7 cells
could increase the expression of CLDN6, and suggested
that the deacetylase inhibitor TSA may partly relax
demethylated chromatin and activate transcription.
Additional studies are needed to determine the exact
molecular mechanism of DNA methylation, and whether
there is a link between DNA methylation and histone dea-
cetylation. Our study showed MeCP2 was a key protein
that bound to methylated DNA regions and recruited
HDACs, and formed complexes that leaded to histone
deacetylation and silenced the transcriptional activity of
that region of the genome [17, 28, 27]. Our ChIP assay
experiments indicated that MeCP2 did interact with the
CLDN6 promoter in MCF-7 cells in vitro, we presumed
that methylated DNA might recruit MeCP2, which can
recruit HDACs to repress CLDN6 expression. It is pos-
sible to have other potential recruited complexes for
methylation.
Conclusion
CLDN6 expression is related to DNA methylation in
breast cancer tissues and MCF-7 cells. DNA methylation
of CLDN6 gene down-regulates its expression by recruit-
ing MeCP2, deacetylating H3 and H4, and altering chro-
matin structure. Down-regulation of CLDN6 expression
could facilitate migratory and invasive phenotype in breast
cancer cells.
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